OKYO Stock Forecast & Price Target

OKYO Pharma Ltd has demonstrated significant progress in the clinical development of urcosimod, a promising therapeutic for inflammatory eye diseases and chronic pain. Specifically, the clinical trial results indicate that 67% of patients receiving the 0.05% urcosimod formulation experienced over 50% improvement in pain, compared to only 33% in the placebo group, with marked reductions in pain scores observable as early as Week 4. These compelling outcomes contribute to a positive outlook for the company, suggesting strong potential for future advancements in its therapeutic pipeline and overall financial performance.

OKYO Pharma Ltd reported a net loss of $4.7 million, or $0.12 per share, for the fiscal year ending March 31, 2025, indicating ongoing financial difficulties. Additionally, the company faces significant risks related to its key product, urcosimod, including potential failures in clinical trials, regulatory approval hurdles, and challenges in achieving market penetration amid competition. The worse baseline condition of patients in the 0.05% urcosimod group compared to the placebo group raises concerns regarding the efficacy of urcosimod, further complicating its commercial viability.